EE05423B1 - IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon - Google Patents

IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon

Info

Publication number
EE05423B1
EE05423B1 EEP200200463A EEP200200463A EE05423B1 EE 05423 B1 EE05423 B1 EE 05423B1 EE P200200463 A EEP200200463 A EE P200200463A EE P200200463 A EEP200200463 A EE P200200463A EE 05423 B1 EE05423 B1 EE 05423B1
Authority
EE
Estonia
Prior art keywords
inhibitor
manufacture
medicament
prevention
treatment
Prior art date
Application number
EEP200200463A
Other languages
English (en)
Estonian (et)
Inventor
Chvatchko Yolande
Dinarello Charles
Plater-Zyberk Christine
Van Deventer Santer
Rubinstein Menachem
Novick Daniela
Kim Soo-Hyun
Original Assignee
Applied Research Systems Ars Holding N.V.
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V., Yeda Research And Development Co. Ltd. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200200463A publication Critical patent/EE200200463A/xx
Publication of EE05423B1 publication Critical patent/EE05423B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EEP200200463A 2000-02-21 2001-02-20 IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon EE05423B1 (et)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00103590 2000-02-21
EP00103597 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Publications (2)

Publication Number Publication Date
EE200200463A EE200200463A (et) 2003-12-15
EE05423B1 true EE05423B1 (et) 2011-06-15

Family

ID=27439934

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200463A EE05423B1 (et) 2000-02-21 2001-02-20 IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon

Country Status (31)

Country Link
US (1) US20030157094A1 (el)
EP (1) EP1257292B1 (el)
JP (1) JP4744763B2 (el)
KR (3) KR20070087256A (el)
CN (1) CN1322897C (el)
AT (1) ATE506959T1 (el)
AU (2) AU4063601A (el)
BG (1) BG66134B1 (el)
BR (1) BR0108514A (el)
CA (2) CA2399298C (el)
CY (1) CY1111687T1 (el)
CZ (1) CZ304485B6 (el)
DE (1) DE60144514D1 (el)
DK (1) DK1257292T3 (el)
EA (1) EA005583B1 (el)
EE (1) EE05423B1 (el)
HK (1) HK1051965A1 (el)
HR (1) HRP20020652A2 (el)
HU (1) HU227752B1 (el)
IL (2) IL151388A0 (el)
ME (1) ME00546B (el)
MX (1) MXPA02008079A (el)
NO (1) NO331971B1 (el)
NZ (3) NZ546294A (el)
PL (1) PL206549B1 (el)
PT (1) PT1257292E (el)
RS (1) RS51737B (el)
SI (1) SI1257292T1 (el)
SK (1) SK288032B6 (el)
TR (2) TR200502508T2 (el)
WO (1) WO2001062285A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
SI1257292T1 (sl) * 2000-02-21 2011-08-31 Merck Serono Sa Uporaba inhibitorjev za il-18
EP1331943A4 (en) 2000-10-11 2005-01-26 Viron Therapeutics Inc NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNOMODULATION
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
BR0210904A (pt) * 2001-05-16 2005-08-16 Yeda Res & Dev Uso de inibidores de il-18 para o tratamento ou prevenção de sepse
MXPA04002565A (es) * 2001-11-30 2004-05-31 Pfizer Prod Inc Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
EP1587530A2 (en) * 2003-01-20 2005-10-26 VIB vzw The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors
CA2523912A1 (en) 2003-04-30 2004-11-11 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
CA2545733A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP5069000B2 (ja) 2004-06-30 2012-11-07 敦生 関山 非炎症性ストレス応答の指標剤およびその利用
US7887802B2 (en) 2004-07-16 2011-02-15 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
DK2267024T3 (da) 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
CA2610804C (en) 2005-06-10 2013-11-19 Ares Trading S.A. Process for the purification of il-18 binding protein
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
EP2027157B1 (en) 2006-05-25 2014-08-06 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
UA125204C2 (uk) 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
MY194040A (en) * 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
US20210115131A1 (en) * 2018-06-14 2021-04-22 Université De Bordeaux Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1
EP4371573A1 (en) 2021-07-13 2024-05-22 National University Corporation Tokai National Higher Education and Research System Medicinal composition for treating inflammatory bowel disease
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
EP0936923B1 (en) * 1996-11-15 2003-12-17 Kennedy Institute Of Rheumatology SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
SI1257292T1 (sl) * 2000-02-21 2011-08-31 Merck Serono Sa Uporaba inhibitorjev za il-18
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
ME00546B (me) 2011-10-10
RS51737B (sr) 2011-10-31
EE200200463A (et) 2003-12-15
AU2001240636B2 (en) 2005-10-13
BG107018A (bg) 2003-09-30
SK12082002A3 (sk) 2003-05-02
TR200202030T2 (tr) 2003-01-21
NO20023962D0 (no) 2002-08-20
HUP0300061A3 (en) 2005-09-28
CZ20022843A3 (cs) 2003-02-12
PT1257292E (pt) 2011-07-05
HU227752B1 (en) 2012-02-28
EP1257292A1 (en) 2002-11-20
BR0108514A (pt) 2002-12-17
BG66134B1 (bg) 2011-06-30
EA200200890A1 (ru) 2003-02-27
JP2003523403A (ja) 2003-08-05
YU60402A (sh) 2005-09-19
HK1051965A1 (en) 2003-08-29
ATE506959T1 (de) 2011-05-15
EP1257292B1 (en) 2011-04-27
HUP0300061A2 (hu) 2003-04-28
AU4063601A (en) 2001-09-03
TR200502508T2 (tr) 2007-04-24
CA2399298A1 (en) 2001-08-30
CN1404400A (zh) 2003-03-19
CA2683009A1 (en) 2001-08-30
SI1257292T1 (sl) 2011-08-31
US20030157094A1 (en) 2003-08-21
PL206549B1 (pl) 2010-08-31
NO20023962L (no) 2002-08-20
KR20020086540A (ko) 2002-11-18
EA005583B1 (ru) 2005-04-28
CN1322897C (zh) 2007-06-27
CA2683009C (en) 2014-09-23
WO2001062285A1 (en) 2001-08-30
CY1111687T1 (el) 2015-10-07
NZ535299A (en) 2006-06-30
NO331971B1 (no) 2012-05-14
MXPA02008079A (es) 2003-02-27
PL357554A1 (en) 2004-07-26
AU2001240636B8 (en) 2005-11-03
CZ304485B6 (cs) 2014-05-28
DE60144514D1 (de) 2011-06-09
IL151388A0 (en) 2003-04-10
NZ520122A (en) 2005-04-29
DK1257292T3 (da) 2011-07-18
CA2399298C (en) 2014-04-15
SK288032B6 (sk) 2012-12-03
HRP20020652A2 (en) 2004-12-31
KR20070087256A (ko) 2007-08-27
KR20070057282A (ko) 2007-06-04
IL151388A (en) 2009-09-01
JP4744763B2 (ja) 2011-08-10
NZ546294A (en) 2008-02-29

Similar Documents

Publication Publication Date Title
EE05423B1 (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
EE04111B1 (et) Raku adhesiooni inhibiitorid, nende kasutamine janeid sisaldavad farmatseutilised kompositsioonid
GB0223040D0 (en) Therapeutic compounds
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0008060A (pt) Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica
GB0005251D0 (en) Therapeutic compounds
RS20110578A2 (en) MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
IL172773A0 (en) Formulations for the treatment of arhritis conditions
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004105737A3 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
AR034343A1 (es) Combinaciones farmaceuticas
NO20071399L (no) VLA-4-antagonister
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
RS60604A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
ATE353221T1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
TNSN00242A1 (en) VALDECOXIB COMPOSITIONS

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name